immune checkpoint inhibitor-associated myocarditis
Conditions
Interventions
Case series:Not applicable
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. The included population was patients with malignant tumors with complete clinical data who received immunotherapy and were diagnosed with ICIS related myocarditis between January 2021 and September 2022 at the First Affiliated Hospital of Zhengzhou University; 2. Diagnosis of myocarditis following the diagnostic criteria for myocarditis proposed by bonaca et al: (1) Histopathological features on endomyocardial biopsy or autopsy suggestive of myocarditis; (2) Diagnosis of myocarditis by cardiac magnetic resonance imaging in conjunction with clinical presentation of myocarditis and elevated biomarkers or electrocardiographic evidence; 3. Echocardiography showed new onset wall motion abnormalities along with clinical manifestations of myocarditis, elevated biomarkers, electrocardiographic evidence, and negative coronary angiography.
Exclusion criteria
Exclusion criteria: Patients who did not use ICI by course were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiovascular adverse events; | — |
Countries
China
Contacts
Public ContactDeliang Shen
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed